[Frontiers in Bioscience, Landmark, 22, 117-127, January 1, 2017]

Linking telomere loss and mitochondrial dysfunction in chronic disease

Ana Carlota Gonzalez-Ebsen 1 , Niels Gregersen 1 , Rikke K.J. Olsen 1

1Research Unit for Molecular Medicine, Department for Clinical Medicine, Aarhus University and Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200 Aarhus N, Denmark

TABLE OF CONTENTS

1. Abstract
2. Introduction
3. Telomeres and their structure
4. Telomere elongation and shortening
5. Oxidative stress and telomeres
6. Why the mitochondria?
7. Telomeres and mitochondria biogenesis
8. Relevance to human diseases
9. Perspectives
10. Acknowledgements
11. References

1. ABSTRACT

Telomeres and mitochondria are known to deteriorate over time. Telomere shortening is associated with aging, early senescence, and premature cell death. Mitochondrial dysfunction produces indiscriminate amounts of reactive oxygen species that may lead to oxidative damage to cellular constituents, including telomeric DNA, causing telomere shortening. In fact, patients with primary mitochondrial dysfunction (for example respiratory chain disorders) and secondary mitochondrial dysfunction (such as metabolic diseases, neurodegenerative diseases, cardiovascular diseases, and mood disorders, among others) have shorter telomeres compared to those of healthy controls. Drawing a mechanistic connection between telomere function and mitochondria biology will provide a broader perspective for understanding the pathophysiology of diseases and their relation to the aging process, and may provide opportunities for new possible treatments.

2. INTRODUCTION

Organisms are unable to live forever. Cells have a finite lifespan; as time passes cells deteriorate and decline in function, giving rise to diseases and death. This process is aging. Mitochondria are key players involved in this process; however, they are rarely in the spotlight. With time, mitochondrial function declines and contributes to the aging process. Two important forces that add to this scenario are impaired ATP production and increased production of reactive species, including oxygen species (ROS) and nitrogen species (RNS) (1-4). At physiological levels, mitochondrial ROS/RNS are important signaling molecules that can activate cellular repair functions such as the antioxidant, protein quality control, autophagy/mitophagy and anti-inflammatory systems through redox modifications of gene and protein networks. In sick cells, however, ROS production increases and the cellular repair functions are no longer able to cope with the increased levels of ROS. As a consequence, irreversible oxidative modifications are increasingly introduced and healthy redox signaling of repair functions are disturbed, leading to oxidative and redox stress (2, 5). Accordingly, many age-related chronic conditions (cardiovascular diseases, diabetes, aging, mood disorders, among others) are associated with overproduction of ROS and oxidative damage (6-9). Specifically, ROS may induce DNA damage to telomeres, the structures that cap chromosome ends (10, 11). Telomere damage may result in accelerated telomere shortening and activation of the DNA damage response (DDR). When telomere length has reached a critical point, cells arrest to halt proliferation and the tumor suppressor protein, p53, is activated in order to induce apoptosis. Also, p53 inhibits the master regulator of mitochondrial biogenesis, peroxisome proliferator-activated receptorγ (PPARγ) co-activator 1α (PGC1-α), which further decreases renewal of mitochondria and causes accumulation of damaged mitochondria (12). This draws a clear connection between mitochondrial function and telomere maintenance. This concept is of particular interest because it may shed some novel light on the pathology and mechanisms of chronic diseases. In the present review we will summarize the current knowledge on telomeres and discuss their close connection to mitochondrial function and impact on human diseases, with the hope that it may inspire development of new combinations of biomarkers of mitochondrial dysfunction and new targets for treatment.

3. TELOMERES AND THEIR STRUCTURE

In 1938, Hermann Muller first identified a recurring structure located at chromosome ends, which he then named telomeres (13). Telomeres are nucleoprotein complexes located at the physical end of linear chromosomes, in eukaryotic cells (14) (Figure 1). These structures are composed of a guanine-rich sequence (TTAGGGG) positioned in a 5’→3’ orientation (14). Telomeres’ termini consist of a 3’ overhang that is subsequently stabilized into a ‘lasso’ or loop structure by interacting proteins of the Shelterin complex (14-19). The lasso-like structure safeguards telomeric DNA, shielding it from degradative enzymes. The Shelterin complex involves the assembly of the following proteins: human telomeric repeat factors: TRF1 and TRF2, protection of telomeres 1 (POT1), TRF1-interacting nuclear factor 2 (TIN2), tripeptidyl-peptidase 1 (TPP1), and Ras proximate 1 (Rap1) (16).

Shelterin protects telomeres by changing their shape (16); when these proteins bind, they cap the telomeres preventing them from being recognized as a double-strand break and keeping the DNA molecule from entering breakage/fusion/bridge cycles (15). The exact mechanism of how Shelterin is able to modify telomeres remains unknown. However, it has been proposed that the t-loop (telomere-loop) formation is what stabilizes the structure (15, 20). By the action of TRF1 and TRF2, the 3’ overhang folds back and is ‘tucked in’, forming a D-loop with the adjacent strand. TRF2 helps localize the D-loop and the ‘tucking in’ of the overhang given that it has been found to be localized at the base of the t-loop (16, 20). TRF1 might aid in the t-loop formation as it catalyzes telomeric synapsis, which leads to a coiled structure (20). POT1 can bind to the duplex end and block telomerase (16). Shorter telomeres have reduced amounts of Shelterin and therefore reduced amounts of POT1; this increases the chances for telomerase to bind and elongate telomeres.

4. TELOMERE ELONGATION AND SHORTENING

With each replication and cell division, telomeres shorten in length (14). Using human diploid fibroblasts, Leonard Hayflick established that they, in fact, had a finite lifespan. And he suggested that this was due to an internal molecular process (21). Years later, Alexei Olovnikov foresaw that the finite lifespan of cells in culture could be attributed to a shortening in their telomeres (22). It was then suggested that telomeres were drivers of replicative senescence in normal cells, and the length could perhaps be used as a ‘tool’ to count the number of cell divisions (23, 24). Nowadays, we know that the length of telomeres does indeed deteriorate with aging in human fibroblasts (25).

Telomeres are maintained by the telomere terminal transferase, telomerase, which consists of a ribonucleoprotein subunit (TERT) (26) and a reverse transcriptase catalytic subunit (TERC) (27). The enzyme is able to elongate chromosome ends through TERT, which provides an RNA template from where the necessary nucleotides are synthesized and added to the DNA strand (14). In the absence of telomerase, as it is the case in most mammalian somatic cells, telomeres shorten with every replication, cell division, and aging (15). When telomeres are unable to protect a chromosome, the outcome could be highly deleterious. The cell will most likely attempt to fix the situation through non-homologous end joining or homologous recombination, which can lead to end-to-end fusions, and ultimately genomic instability and possibly cancer (15, 28). Under normal conditions, telomere dysfunction is detected and the DNA damage response (DDR) is activated (29). Upstream kinases, ataxia telangiectasia (ATM) and Rad3-related protein (ATR) are activated and are able to phosphorylate checkpoint kinase 1 (CHK1) and checkpoint kinase 2 (CHK2), which consequently phosphorylate p53, a tumor suppressor that induces apoptosis and cellular senescence, through p21, to halt the growth of damaged cells (30) (Figure 2).

Three different mechanisms have been put forth on telomere shortening: the end of replication problem, which consists of the inability of DNA polymerase to fully replicate the lagging strand (23). Activation of C-strand exonuclease (31), which degrades both ends of the chromosome after DNA replication in order to allow the formation of the 3’ overhang. And lastly, the main focus of this review: oxidative stress, which can not only cause DNA damage, but can also shorten telomeres (11).

5. OXIDATIVE STRESSS AND TELOMERES

Oxidative stress is able to cause DNA damage in the form of oxidized bases and single/double strand breaks; in fact, acute oxidative stress increases the frequency of double-strand breaks (11). Telomeres are particularly susceptible to oxidative stress because their composition is rich in guanine sequences, which are vastly vulnerable to oxidation (10). Oikawa et al. showed that one of the main ROS, hydroxyl radical, promotes 8-oxo-7,8-dihydro-2’-deoxyguanosine (8-oxodG) at the 5’ site of telomeric 5’-GGG-3’. Telomere shortening requires DNA replication (26, 32-34). Unrepaired nucleotides in telomeres, due to oxidative damage, disrupt the replication fork and thus amplify the amount of unreplicated ends (11). Further, oxidative damage can disrupt telomere maintenance by reducing telomerase activity and accelerating telomere shortening, as it has been observed in vascular smooth muscle, leukemic, and endothelial cells (35-38). The rate of telomere shortening varies among cells, depending on ROS and antioxidant production, and telomere length shortens at a faster rate when exposed to oxidative stress, suggesting that telomeres may act as biomarkers of accumulative oxidative damage and indicators of disease development (11, 39). Chronic stress conditions such as mild hyperoxia, hydrogen peroxide, radiation, organic hydroperoxides, or transfection with oncogenes leads to premature senescence and activation of p53 (34, 40-42). Accelerated telomere shortening, however, may be slowed when oxidative stress is reduced to levels below those of the required threshold (11, 39), using free radical scavengers, antioxidants, and low oxygen concentrations (43-45). These in vitro studies show a relationship between oxidative stress and telomere shortening.

Human population studies have shown a similar relationship between oxidative stress and telomere shortening. In these cases, oxidative stress and telomere shortening were associated with obesity, smoking, psychological/economical stress, and different types of cardiovascular diseases (46-48), as discussed in more details below. von Zglinicki and others have proposed that the link between these phenomena is found in mitochondria (49), the major production site of ROS (50, 51).

6. WHY THE MITOCHONDRIA?

Studies where the mitochondria specific antioxidant, MitoQ, was targeted to mitochondria, counteracted telomere shortening and lengthened the lifespan of cells by 40% under hyperoxia (52). Similar, treatment with nicotinamide has also been shown to stall telomere attrition and prolong lifespan (53). Nicotinamide is a precursor of NAD+, which as a co-factor to a number of metabolic enzymes including the sirtuins, is essential in maintaining mitochondrial function and decreasing cellular ROS (54). Moreover, severe mitochondrial depolarization in mouse embryos, by FCCP (carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone), led to an increased production of ROS, telomere shortening, and chromosome fusion (55), suggesting a connection between telomeres and mitochondrial ROS production.

During oxidative stress, the TERT component of telomerase have been shown to translocate to the mitochondria, thus preventing telomere elongation (35, 56-58). This suggests that mitochondria protection is of higher priority than telomere maintenance. Ahmed et al. have shown that overexpression of TERT, in fibroblasts, protects mtDNA from acute/chronic oxidative damage by increasing mitochondrial membrane potential, and decreasing both mitochondrial and cellular ROS levels. However, the exact mechanism as to how telomerase protects mitochondria is unclear; does it protects against mtDNA oxidation, triggers repair of damaged mtDNA, elicits degradation of damaged mitochondria, or is it due to the decrease in ROS levels? This uncertainty requires further elucidation. Recent studies, however, suggest that TERT may protect mitochondrial function indirectly by regulation of mitochondrial biogenesis.

7. TELOMERES AND MITOCHONDRIAL BIOGENESIS

Mitochondrial biogenesis is the process by which healthy mitochondria divide and grow while damaged mitochondria are removed (59). It depends on coordinated transcriptional control of genes coding for proteins essential for mitochondrial function, repair and structure. Peroxisome proliferator-activated receptor γ (PPARγ) co-activator (PGC-1α) is the master regulator of mitochondria biogenesis (60) and is phosphorylated and activated by AMP-activated protein kinase (AMPK). In addition, PGC-1α enables expression of sirtuin 1 (SIRT1), which is necessary for the activation of AMPK (60).

In an aging model, p53 activation in response to the DNA damage response, leads to suppression of AMPK and mitochondrial dysfunction (61). Similarly, studies of mice with TERT deficiency and telomere dysfunction showed compromised mitochondrial biogenesis and function in various tissues such as liver and heart (12). These observations were shown to be caused by suppression of PGC-1α and PGC-1β and their downstream targets such as genes that are required for oxidative phosphorylation, β-oxidation of fatty acids, gluconeogenesis, and ROS defense; it resulted in disturbed oxidative phosphorylation, diminished ATP production, compromised gluconeogenic capacity, and increased ROS, signifying a clear connection between mitochondria and telomere function (12). Sahin et al. suggested that telomere dysfunction leads to DDR activation, and consequent activation of p53, which binds to PGC-1α/PGC-1β promoters and represses expression of PGC-1α/PGC-1β and their downstream targets. As a consequence, mitochondria biogenesis declines and ROS levels increase (12, 62). In another study, removal of PGC-1α in apolipoprotein knockout mice, by Xiong et al., showed oxidative stress, telomere dysfunction and shortening, DNA damage, accelerated aging, and atherosclerosis (63). This further emphasizes the key role of PGC-1α in the system and suggests a vicious cycle of mitochondrial and telomere dysfunction (Figure 3).

Although these studies show that p53 decreases mitochondrial biogenesis controlled by the AMPK/PGC-1α,β axis, other studies have shown that p53 activates the AMPK/PGC-1α,β axis and increases mitochondrial function and oxidative defense mechanisms. The exact mechanisms that control different outcomes of p53 activation still need to be elucidated. However, it has been suggested that p53 may switch from a pro-survival to a pro-aging or pro-apoptotic protein depending on its activity level, which may be controlled by the severity of oxidative damage (62). These mechanistic links between mitochondrial biogenesis and telomere function seem relevant in order to understand the contribution of mitochondrial and telomere dysfunction to the aging process (3,62). PGC-1α and PGC-1β are known to decrease in chronic diseases, including aging, which results in mitochondrial dysfunction and increased production of ROS, which can cause mtDNA mutations and further ROS production. Under mild stress levels, p53 activation will allow activation of AMPK/PGC-1α,β to repair and maintain cellular functions. At higher levels of ROS, or when telomeric damage accumulates to a level required to activate the DDR, TERT exits the nucleus and p53 is activated to inhibit mitochondrial biogenesis, and initiate pro-aging senescence. This may be an adaptive mechanism to prevent further ROS production from a damaged mitochondrial network and necrotic cell death. At even more excessive stress levels, p53 seems to by-pass the AMPK/PGC-1α,β axis and activates apoptosis to eliminate cells that are too damaged to survive. Functional consequences of p53 may also be tissue dependent. In tissues with a higher turnover demand, for example blood cells, the system can afford to lose cells by apoptosis; and in tissues with a lower turnover demand, for example in the brain, it is more affordable for the system to inhibit mitochondrial function rather than lose cells (3). In our opinion, both scenarios are a defense mechanism very much dependent on the tissue’s needs.

One of the previous aging models suggests that mitochondrial dysfunction, in the form of oxidative stress and inflammation, may accelerate telomere shortening in post-mitotic tissue, and therefore individuals carrying cells with excessive oxidative damage may experience cellular senescence and premature aging/disease (64). On the other hand, studies by Sahin et al, which revealed that telomere dysfunction in itself can induce mitochondrial dysfunction and oxidative damage (12, 62), have promoted the idea that telomere length to some extent may be the preceding factor, so that individuals, who were born with short telomeres are already predisposed to developing mitochondrial dysfunction, diseases, and early aging during adulthood (65). Although this telomere-mitochondrial model supports the idea that telomere shortening may influence mitochondrial dysfunction and vice versa, further studies are required to fully understand how these pathways are connected and activated in different aging and chronic cell stress models. Moreover, the studies that closely associate mitochondria and telomeres (12, 62) have been done in genetically modified mice. Even though animal models have provided understanding in biology, one cannot assume that this scenario will be applicable to humans. However, a recent study by Tyrka et al showed a relationship between telomere function and mitochondrial biology. This study showed that in human whole blood samples, longer telomeres related to a higher mitochondrial DNA copy number. This suggests the possibility that similar mechanistic links between mitochondrial function and telomere biology may also exist in humans (65). Below, we will briefly discuss telomere dysfunction in some chronic diseases, where mitochondrial dysfunction and oxidative stress are known to be important players in initiation or progression of disease development.

8. RELEVANCE TO HUMAN DISEASES

Patients with Friedreich’s Ataxia (FRDA) suffer from a hereditary central nervous system condition, which consists of decreased frataxin, a mitochondrial protein involved in the formation of iron-sulfur clusters (66). This leads to mitochondrial dysfunction and overproduction of ROS, making the cell more vulnerable to oxidative stress. Oxidative stress and inflammation are thought to contribute to telomere shortening in leukocytes of FRDA patients (67). In fact, telomere loss in patients with FRDA was significantly higher when compared to healthy controls (67). Patients that have suffered from the disease for a longer period of time have been reported to possess notably shorter telomeres, suggesting that telomere length could be used as a biomarker of disease progression (67). Patients with other primary mitochondrial dysfunction, as it is the case for respiratory chain disorders, such as mitochondrial myopathy, encephalopathy, lactic acid, and stroke (MELAS) and leber hereditary optic neuropathy (LHON) have also been shown to have shorter telomeres in their white blood cells, when compared to controls (68). In addition, patients with mitochondrial diabetes caused by mitochondrial DNA mutation (m.3243A>G), have also been shown to have shorter leukocyte telomere length compared to controls, suggesting a connection between telomere length and disease development (69). Mitochondrial dysfunction with increased mitochondrial ROS production is a hallmark of these disorders (5,70). The exact mechanism by which ROS production is initiated and propagated in human diseases are not known. However, disturbances in the integrity of the respiratory chain seem to play a principal role in both primary and secondary mitochondrial diseases, as discussed in (2). Primary mitochondrial disorders have been shown to produce ROS by increased electron leakage from the affected mitochondrial respiratory chain. Mitochondrial DNA is, because of its proximity to the site of ROS production, prone to oxidative damage, which can cause further respiratory chain damage and electron leakage initiating a vicious cycle of ROS production (71). This connection between telomere and mitochondrial dysfunction seems not to be exclusive to mitochondrial or nuclear gene defects that directly affect mitochondrial components, as telomere shortening has been observed in other chronic diseases, where mitochondrial dysfunction is induced by some external and yet less defined mechanisms.

Telomere shortening has been shown in a variety of psychological disorders (6). Peripheral blood mononuclear cells of highly stressed women (46) and leukocytes of individuals with major depressive disorder, bipolar disorder, anxiety, and post-traumatic stress disorder (6,72) showed an accelerated telomere shortening, which may explain the increased mortality and morbidity seen in these conditions. These psychological disorders are also associated with mitochondrial dysfunction and oxidative stress that may cause DNA damage (73-75).

Moreover, patients suffering from diabetes type 1 or 2, cardiovascular diseases and atherosclerosis have also been reported to have shorter leukocyte telomere length when compared to controls (76-81). Similar, Parkinson’s and Alzheimer’s disease have been shown to have accelerated shortening of telomeres in leukocytes or peripheral blood mononuclear cells (82-84). Decline in mitochondrial function (for example, downregulation of oxidative phosphorylation) and increase in mitochondrial DNA damage as well as oxidative stress also contribute to the development of these diseases (85-89), suggesting a linkage between telomere shortening and mitochondrial dysfunction also in these diseases. Thus, telomere shortening and mitochondrial dysfunction seem to be a general finding in many age-associated diseases, such as neurodegenerative diseases, atherosclerosis, and cardiovascular disease, supporting the importance of the telomere-mitochondria axis. However, for most of these conditions the cellular mediators are still unknown, and future work may show if telomere shortening in all cases relate to decreased PGC-1α/β and mitochondrial biogenesis.

9. PERSPECTIVES

As discussed in the present review, emerging data suggest a connection between telomeres and mitochondria. They seem to exist in a dependent cycle, where the dysfunction of one of the systems worsens the condition of the other, adding further strain to the cells’ overall health. There are indeed many aspects of the mitochondria-telomere axis that need to be unraveled, and further human studies are required to determine the applicability of the discussed model to humans. Nonetheless, a deeper understanding of the intricate pathways and mechanisms, which link mitochondrial dysfunction and telomere shortening, may provide a broader perspective for understanding the contribution of mitochondrial dysfunction to age-related diseases, not to mention that it could open the door to discovering new treatments.

Moreover, the fact that telomere length may be an indicator of accumulative oxidative damage potentially makes it an ideal biomarker of the extent of mitochondrial dysfunction and chronic cell stress. To this comes that the measuring of telomeres can be performed in blood, which is a stable and easy-to-access sample. Implementation of telomere length as biomarker for chronic cell stress may promote clearer identification of patients for future research studies, and in the long run improve diagnostics, prognostics, and treatment of chronic diseases.

10. ACKNOWLEDGEMENTS

This review paper was supported by the Danish Council of Independent Medical Research (#4004-00548), Aarhus County Research Initiative, Department for Clinical Medicine, and the Faculty of Health, Aarhus University.

11. REFERENCES

1. Choon Park D, Geun Yeo S: Aging. Korean J Audiol 17, 39-44 (2013)
DOI: 10.7874/kja.2013.17.2.39

2. Olsen RK, Cornelius N, Gregersen N: Redox signaling and mitochondrial stress responses; lessons from inborn errors of metabolism. J Inherit Metab Dis 38, 703-719 (2015)
DOI: 10.1007/s10545-015-9861-5

3. Kelly DP: Ageing theories unified. Nature 470, 342-343 (2011)
DOI: 10.1038/nature09896

4. Wang CH, Wu SB, Wu YT, Wei YH: Oxidative stress response elicited by mitochondrial dysfunction: implication in the pathophysiology of aging. Exp Biol Med 238 (5), 450-460 (2013)
DOI: 10.1177/1535370213493069

5. Olsen RK, Cornelius N, Gregersen N: Genetic and cellular modifiers of oxidative stress: what can we learn from fatty acid oxidation defects? Mol Genet Metab S31-S39 (2013)
DOI: 10.1016/j.ymgme.2013.10.007

6. Lindqvist D, Epel ES, Mellon SH, Penninx BW, Revesz D, Verhoeven JE, Reus VI, Lin J, Mahan L, Hough CM et al : Psychiatric disorders and leukocyte telomere length: Underlying mechanisms linking mental illness with cellular aging. Neurosci Biobehav Rev 55, 333-364 (2015)
DOI: 10.1016/j.neubiorev.2015.05.007

7. Ha H, Hwang I-A, Park JH, Lee HB: Role of reactive oxygen species in the pathogenesis of diabetic nephropathy. Diabetes Res Clin Pract 82S, S42-S45 (2008)
DOI: 10.1016/j.diabres.2008.09.017

8. Junqueira VB, Barros SB, Chan SS, Rodrigues L, Giavarotti L, Abud RL, Deucher GP: Aging and oxidative stress. Mol Aspects Med 25, 5-16 (2004)
DOI: 10.1016/j.mam.2004.02.003

9. Griendling KK, FitzGerald GA: Oxidative stress and cardiovascular injury Part I: basic mechanisms and in vivo monitoring of ROS. Circulation 108, 1912-1916 (2003)
DOI: 10.1161/01.CIR.0000093660.86242.BB

10. Oikawa S, Kawanishi S: Site-specific DNA damage at GGG sequence by oxidative damage may accelerate telomere shortening. FEBS Lett 453, 365-368 (1999)
DOI: 10.1016/S0014-5793(99)00748-6

11. von Zglinicki T: Oxidative stress shortens telomeres. Trends Biochem Sci 27, 339-344 (2002)
DOI: 10.1016/S0968-0004(02)02110-2

12. Sahin E, Colla S, Liesa M, Moslehi J, Muller FL, DePinho R: Telomere dysfunction induces metabolic and mitochondrial compromise. Nature 470, 359-365 (2011)
DOI: 10.1038/nature09787

13. Muller HJ: The remaking of chromosomes. Collecting Net 13 (8), 181-198 (1938)

14. Blackburn E: Structure and function of telomeres. Nature 350 (6319), 569-573 (1991)
DOI: 10.1038/350569a0

15. Bailey SM, Murname JP: Telomeres, chromosome instability and cancer. Nucleic Acids Res 34 (8), 2408-2417 (2006)
DOI: 10.1093/nar/gkl303

16. de Lange T: Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev 19, 2100-2110 (2005)
DOI: 10.1101/gad.1346005

17. Deng Y, Chang S: Role of telomeres and telomerase in genomic instability, senescence and cancer. Laboratory Invest 87, 1071-1076 (2007)
DOI: 10.1038/labinvest.3700673

18. Deng Y, Chan SS, Chang S: Telomere dysfunction and tumor suppression: in the senescence connection. Nature 8, 450-458 (2008)

19. Wong JMY, Collins K: Telomere maintenance and disease. Lancet 362, 983-988 (2003)
DOI: 10.1016/S0140-6736(03)14369-3

20. Griffith JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, de Lange T: Mammalian telomeres end in large duplex loop. Cell 97, 503-514 (1999)
DOI: 10.1016/S0092-8674(00)80760-6

21. Hayflick L, Moorhead PS: The serial cultivation of human diploid cell strains. Exp Cell Res 25, 585-621 (1961)
DOI: 10.1016/0014-4827(61)90192-6

22. Olovnikov AM: Telomeres, telomerase, and aging: origin of the theory. Exp Gerontol 31, 443-448 (1996)
DOI: 10.1016/0531-5565(96)00005-8

23. Olovnikov AM: Principle of marginotomy in template synthesis of polynucleotides. Dokl Akad Nauk SSSRR 201, 1496-1499 (1971)
No DOI found

24. Watson JD: Origin of concatemeric T7 DNA. Nat New Biol 239, 197-201 (1972)
DOI: 10.1038/newbio239197a0

25. Harley CB, Futcher B, Greider CW: Telomeres shorten during ageing of human fibroblasts. Nature 345, 458-460 (1990)
DOI: 10.1038/345458a0

26. Feng J, Funk WD, Wang S-S, Weinrich SL, Avilion AA, Chiu C-P, Adams RR, Chang E, Allsopp RC, Yu J et al : The RNA component of human telomerase. Science 269, 1236-1241 (1995)
DOI: 10.1126/science.7544491

27. Nakamura TM, Cech TR: Reversing time: origin of telomerase. Cell 92, 587-590 (1998)
DOI: 10.1016/S0092-8674(00)81123-X

28. Ricchetti M, Dujon B, Fairhead C: Distance from the chromosome end determines the efficiency of double-strand break. J Mol Biol 328, 847-862 (2003)
DOI: 10.1016/S0022-2836(03)00315-2

29. d’Adda di Fagagna F, Reaper PM, Clay-Ferrace L, Fiegler H, Carr P, von Zglinicki T, Saretzki G, Carter NP, Jackson SP: A DNA damage checkpoint response in telomere-initiated senescence. Nature 426, 194-198 (2003)
DOI: 10.1038/nature02118

30. Gire V, Roux P, Wynford-Thomas D, Brondello J-M, Dulic V: DNA damage checkpoint kinase Chk2 triggers replicative senescence. EMBO J 23, 2554-2563 (2004)
DOI: 10.1038/sj.emboj.7600259

31. Makarov VL, Hirose Y, Langmore JP: Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for telomere shortening. Cell 88, 657-666 (1997)
DOI: 10.1016/S0092-8674(00)81908-X

32. Munro J, Steeghs K, Morrison V, Ireland H, Parkinson KE: Human fibroblast replicative senescence can occur in the absence of extensive cell division and short telomeres. Oncogene 24, 885-893 (2001)
DOI: 10.1038/sj.onc.1204460

33. Sitte N, Sarietzki G, von Zglinicki T: Accelerated telomere shortening in fibroblasts after extended periods of confluency. Free Radic Biol Med 24, 885-893 (1998)
DOI: 10.1016/S0891-5849(97)00363-8

34. von Zglinicki T, Saretzki G, Docke W, Lotze C: Mild hyperoxia shortens telomeres and inhibits proliferation of human fibroblasts: a model for senescence? Exp Cell Res 220, 186-193 (1995)
DOI: 10.1006/excr.1995.1305

35. Haendeler J, Hoffman J, Diehl FJ, Vasa M, Spyridopoulus I, Zeither AM, Dimmeler S: Antioxidants inhibit nuclear export of telomerase reverse transcriptase and delay replicative senescence of endothelial cells. Circ Res 94, 768-775 (2004)
DOI: 10.1161/01.RES.0000121104.05977.F3

36. Kurz DJ, Decary S, Hong Y, Trivier E, Akhmedov A, Eruslimsky JD: Chronic oxidative stress compromises telomere integrity and accelerates the onset of senescence in human endothelial cells. J Cell Sci 117, 2417-2426 (2004)
DOI: 10.1242/jcs.01097

37. Matthews C, Gorenne I, Scott S, Figg N, Kirkpatrick P, Ritchie A, Goddard M, Bennett M: Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis: effects of telomerase and oxidative stress. Circ Res 99, 156-164 (2006)
DOI: 10.1161/01.RES.0000233315.38086.bc

38. Pizzimenti S, Briatore F, Laurora S, Toaldo C, Maggio M, De Grandi M, Meaglia L, Menegatti E, Giglioni B, Dianzani MU et al : 4-Hydroxynonenal inhibits telomerase activity and hTERT expression in human leukemic cell lines. Free Radic Biol Med 40, 1578-1591 (2006)
DOI: 10.1016/j.freeradbiomed.2005.12.024

39. Passos JA, Saretzki G, Ahmed S, Nelson G, Richter T, Peters H, Wappler I, Birket MJ, Harold G, Schaeuble K et al : Mitochondrial dysfunction accounts for stochastic heterogeneity in telomere-dependent senescence. PLoS Biol 5, e110 (2007)
DOI: 10.1371/journal.pbio.0050110

40. Chen Q, Ames BN: Senescence-like growth arrest induced by hydrogen peroxide in human diploid fibroblast F65 cells. Proc Natl Acad Sci U S A 91, 4130-4134 (1995)
DOI: 10.1073/pnas.91.10.4130

41. Palmero I, Pantoja C, Serrano M: p19ARF links the tumour suppressor p53 to Ras. Nature 395, 125-126 (1998)
DOI: 10.1038/25870

42. Toussaint O, Fuchs S, Ronai Ze, Isoyama S, Yuko N, Petronilli V, Bernardi P, Gonos E, Dumont P, Remacle J: Reciprocal relationships between the resistance to stresses and cellular aging. Ann N Y Acad Sci 851, 450-465 (1998)
DOI: 10.1111/j.1749-6632.1998.tb09023.x

43. Forsyth NR, Evans P, Shay JW, Wright WE: Developmental differences in the immortalization of lung fibroblasts by telomerase. Aging Cell 2, 235-243 (2003)
DOI: 10.1046/j.1474-9728.2003.00057.x

44. Richter T, von Zglinicki T: A continuous correlation between oxidative stress and telomere shortening in fibroblasts. Exp Gerontol 42 (11), 1039-1042 (2007)
DOI: 10.1016/j.exger.2007.08.005

45. von Zglinicki T, Pilger R, Sitte N: Accumulation of single-strand breaks is the major cause of telomere shortening in human fibroblasts. Free Radic Biol Med 28, 64-74 (2000)
DOI: 10.1016/S0891-5849(99)00207-5

46. Epel ES, Blackburn EH, Jue L, Dhabhar FS, Adler NE, Morrow JD, Cawthon RM: From the cover: accelerated telomere shortening in response to life stress. Proc Natl Acad Scie U S A 101, 17312-17315 (2004)
DOI: 10.1073/pnas.0407162101

47. Valdes AM, Andrew T, Gardner JP, Kimura M, Oelsner E, Cherkas LF, Aviv A, Spector TD: Obesity, cigarette smoking, and telomere length in women. Lancet 366, 662-664 (2005)
DOI: 10.1016/S0140-6736(05)66630-5

48. von Zglinicki T, Martin-Ruiz CM: Telomeres as biomarkers for ageing and age-related diseases. Curr Mol Med 5 (2), 197-203 (2005)
DOI: 10.2174/1566524053586545

49. Passos JF, Saretzki G, von Zglinicki T: DNA damage in telomeres and mitochondria during cellular senescence: is there a connection? Nucleic Acids Res 35 (22), 7505-7513 (2007)
DOI: 10.1093/nar/gkm893

50. Andreyev A, Kushnareva Y, Starkov A: Mitochondrial metabolism of reactive oxygen species. Biochemistry (Mosc) 70, 200-214 (2005)
DOI: 10.1007/s10541-005-0102-7

51. Adam-Vizi V, Chinopoulos C: Bioenergetics and the formation of mitochondrial reactive oxygen species. Trends Pharmacol Sci 27, 639-645 (2006)
DOI: 10.1016/j.tips.2006.10.005

52. Saretzki G, Murphy MP, von Zglinicki T: MitoQ counteracts telomere shortening and elongates lifespan of fibroblasts under mild oxidative stress. Aging Cell 2, 141-143 (2002)
DOI: 10.1046/j.1474-9728.2003.00040.x

53. Kang HT, Lee HI, Hwang ES: Nicotinamide extends replicative lifespan of human cells. Aging Cell 5, 426-436 (2006)
DOI: 10.1111/j.1474-9726.2006.00234.x

54. Kang H, Hwang E: Nicotinamide enhances mitochondria quality through autophagy activation in human cells. Aging Cell 8, 426-438 (2009)
DOI: 10.1111/j.1474-9726.2009.00487.x

55. Liu L, Trimarchi JR, Smith PJ, Keefe DL: Mitochondrial dysfunction leads to telomere attrition and genomic instability. Aging Cell 1, 40-46 (2002)
DOI: 10.1046/j.1474-9728.2002.00004.x

56. Haendeler J, Hoffmann J, Brandes RP, Zeiher AM, Dimmeler S: Hydrogen peroxide triggers nuclear export of telomerase reverse transcriptase via Src kinase family-dependent phosphorylation of Tyrosine 707. Mol Cell Biol 23, 4598-4610 (2003)
DOI: 10.1128/MCB.23.13.4598-4610.2003

57. Santos JH, Meyer JN, Skorvaga M, Annab LA, Van Houten B: Mitochondrial hTERT exacerbates free-radical-mediated mtDNA damage. Aging Cell 3, 399-411 (2004)
DOI: 10.1111/j.1474-9728.2004.00124.x

58. Santos JH, Meyer JN, Van Houten B: Mitochondrial localization of telomerase as a determinant for hydrogen peroxide-induced mitochondrial DNA damage and apoptosis. Hum Mol Genet 15, 1757-1768 (2006)
DOI: 10.1093/hmg/ddl098

59. Youle RJ, van der Bliek AM: Mitochondrial fission, fusion, and stress. Science 337, 1062-1065 (2012)
DOI: 10.1126/science.1219855

60. Canto C, Auwerx J: PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol 20, 98-105 (2009)
DOI: 10.1097/MOL.0b013e328328d0a4

61. Jones RG, Plas DR, Kubek S, Buzzai M: AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18, 283-293 (2005)
DOI: 10.1016/j.molcel.2005.03.027

62. Sahin E, DePinho RA: Axis of ageing: telomeres, p53 and mitochondria. Nat Rev Mol Cell Biol 13 (6), 397-404 (2012)
DOI: 10.1038/nrm3352

63. Xiong S, Patrushev N, Forouzandeh F, Hilenski L, Alexander RW: PGC1-alpha modulates telomere function and DNA damage in protecting against aging-related chronic diseases. Cell Rep 12, 1391-1399 (2015)
DOI: 10.1016/j.celrep.2015.07.047

64. Aviv A, Kark JD, Susser E: Telomeres, Atherosclerosis, and Human Longevity. Epidemiology 26 (3), 295-299 (2015)
DOI: 10.1097/EDE.0000000000000280

65. Tyrka AR, Carpenter LL, Kao H-T, Porton B, Philip NS, Ridout SJ, Ridout KK, Price LH: Association of telomere length and mitochondrial DNA copy number in a community sample of healthy adults. Exp Gerontol 66,17-20 (2015)
DOI: 10.1016/j.exger.2015.04.002

66. Marmolino D: Friedreich’s ataxia: past, present and future. Brain Res Rev 67, 311-330 (2011)
DOI: 10.1016/j.brainresrev.2011.04.001

67. Castaldo I, Vergara P, Pinelli M, Filla A, De Michele G, Cocozza S, Monticelli A: Can telomere shortening in human peripheral blood leukocytes serve as a disease biomarker of Friedreich’s ataxia? Antioxid Redox Signal 18 (11), 1303-1306 (2013)
DOI: 10.1089/ars.2012.5009

68. Oexle K, Zwirner A: Advanced telomere shortening in chain disorders. Hum Mol Genet 6, 905-908 (1997)
DOI: 10.1093/hmg/6.6.905

69. Zhou M-C, Min R, Ji J-J, Zhang S, Tong A-L, Xu J-p, Li Z-Y, Zhang H-B, Li Y-X: Analysis of association among clinical features and shorter leukocyte telomere length in mitochondrial diabetes with m.3243A>G mitochondrial DNA mutation. BMC Med Genet 16 (92), 1-7 (2015)
DOI: 10.1186/s12881-015-0238-2

70. Kirkinezos IG, Moraes CT: Reactive oxygen species and mitochondrial diseases. Cell Dev Biol 12, 449-457 (2001)
DOI: 10.1006/scdb.2001.0282

71. Wu S, Ma Y, Wu Y, Chen Y, Wei Y: Mitochondrial DNA Mutation-Elicited Oxidative Stress, Oxidative Damage, and Altered Gene Expression in Cultured Cells of Patients with MERRF Syndrome. Mol Neurobiol 41 (2), 256-266 (2010)
DOI: 10.1007/s12035-010-8123-7

72. Simon NM, Smoller JW, McNamara KL, Maser RS, Zalta AK, Pollack MH, Nierenberg AA, Fava M, Wong K-K: Telomere shortening and mood disorders: preliminary support for a chronic stress model of accelerated aging. Biol Psychiatry 60, 432-435 (2006)
DOI: 10.1016/j.biopsych.2006.02.004

73. Irie M, Asami S, Ikedo M, Kasai H: Depressive states relates to female oxidative DNA damage via neutrophil activation. Biochem Biophys Res Commun 311 (4), 1014-1018 (2003)
DOI: 10.1016/j.bbrc.2003.10.105

74. Irie M, Asami S, Nagata S, Miyata M, Kasai H: Relationships between perceived workload, stress and oxidative DNA damage. Int Arch Occup Environ Health 74, 153-157 (2001)
DOI: 10.1007/s004200000209

75. Morris G, Berk M: The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders. BMC Med 13:68 (2015)
DOI: 10.1186/s12916-015-0310-y

76. Olivieri F, Lorenzi M, Antonicelli R: Leukocyte telomere shortening in elderly Type2DM patients with previous myocardial infarction. Atherosclerosis 206, 588-593 (2009)
DOI: 10.1016/j.atherosclerosis.2009.03.034

77. Sampson M, Winterbone M, Hughes J, Dozio N, Hughes D: Monocyte telomere shortening and oxidatie DNA damage in type 2 diabetes. Diabetes Care 29, 283-289 (2006)
DOI: 10.2337/diacare.29.02.06.dc05-1715

78. Uziel O, Singer J, Danicek V: Telomere dynamics in arteries and mononuclear cells of diabetic patients: effect of diabetes and of glycemic control. Exp Gerontol 42, 971-978 (2007)
DOI: 10.1016/j.exger.2007.07.005

79. Matthews C, Gorenne I, Scott S: Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis: effects of telomerase and oxidative stress. Circ Res 99, 156-154 (2006)
DOI: 10.1161/01.RES.0000233315.38086.bc

80. Brouilette S, Singh R, Thompson J, Goodall A, Samani N: White cell telomere length and risk of premature myocardial infarction. Arterioscler Thromb Vasc Biol 23, 842-846 (2003)
DOI: 10.1161/01.ATV.0000067426.96344.32

81. Fitzpatrick A, Kronmal R, Gardner J: Leukocyte telomere length and cardiovascular disease in the cardiovascular health study. Am J Epidemiol 165, 14-21 (2007)
DOI: 10.1093/aje/kwj346

82. Panossian L, Porter V, Valenzuela H, Zhu X, Reback E, Masterman D, Cummings J, Effros R: Telomere shorteningin T cells correlates with Alzheimer’s disease status. Neruobiol Aging 24, 77-84 (2003)
DOI: 10.1016/S0197-4580(02)00043-X

83. Thomas P, O’Callaghan N, Fenech M: Telomere length in white blood cells, buccal cells and brain tissue and its variation with aging and Alzheimer’s disease. Mec Aging Dev 129 (4), 183-190 (2008)
DOI: 10.1016/j.mad.2007.12.004

84. Guan J, Maeda T, Suagno M, Oyama J, Higuchi Y, Suzuki T, Makino N: A percentage analysis of the telomere length in Parkinson’s disease patients. J Gerentol Ser A-Biol Sci Med Sci 63 (5), 467-473 (2008)
DOI: 10.1093/gerona/63.5.467

85. Ryan B, Hoek S, Fon E, Wade-Martins R: Mitochondrial dysfunction and mitophagy in Parkinson’s: from familial to sporadic disease. Trends Biochem Sci 40 (4), 200-210 (2015)
DOI: 10.1016/j.tibs.2015.02.003

86. Swerdlow R, Burns J, Khan S: The Alzheimer’s disease mitochondrial cascade hypothesis: Progress and perspectives. Biochim Biophys Acta 1842 (8), 1219-1231 (2013)
DOI: 10.1016/j.bbadis.2013.09.010

87. Mikhed Y, Daiber A, S. S: Mitochondrial oxidative stress, mitochondrial DNA damage and their role in age-related vascular dysfunction. Int J Mol Sci 16 (7), 15918-15953 (2015)
DOI: 10.3390/ijms160715918

88. Bonomini F, Rodella L, Rezzani R: Metabolic syndrome, aging, and involvement of oxidative stress. Aging Dis 6 (2), 109-120 (2015)
DOI: 10.14336/AD.2014.0305

89. Ward M, Fortheringham A, Cooper M, Forbes J: Targeting advanced glycation end products and mitochondrial dysfunction in cardiovascular diseases. Curr Opin Pharmacol 13 (4), 654-651 (2013)
DOI: 10.1016/j.coph.2013.06.009

90. Correia-Melo C, Hewitt G, Passos JF: Telomeres, oxidative stress and inflammatory factors: partners in cellular senescence. Longev Healthspan 3 (1), 1 (2014)
DOI: 10.1186/2046-2395-3-1

Abbreviations: ROS: reactive oxygen species; RNS: reactive nitrogen species; DDR: DNA damage response; PGC1-α: peroxisome proliferator-activated receptor γ (PPARγ) co-activator 1α; TRF1: telomeric repeat factor 1; TRF2: telomeric repeat factor 2; POT1: protection of telomeres 1; TIN2: TRF1-interacting nuclear factor 2, TPP1: tripeptidyl-peptidase 1; Rap1: Ras proximate 1; FCCP: carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone; TERT: telomerase reverse transcriptase; TERC: telomerase RNA; ATM: ataxia telangiectasia; ATR: ataxia telangiectasia and Rad3-related protein; CHK1: checkpoint kinase 1; CHK2: checkpoint kinase 2; FRDA: Friedreich’s Ataxia; MELAS: mitochondrial myopathy, encephalopathy, lactic acid, and stroke; LHON: Leber’s hereditary optic neuropathy

Key Words: Telomeres, Mitochondrial Dysfunction, Oxidative Stress, Chronic Diseases, Review

Send correspondence to: Ana Carlota Gonzalez-Ebsen, Palle Juul-Jensens Boulevard 39, 8200 Aarhus N, Denmark. Tel: 45 784-55243, Fax: 45 862-78402, E-mail: ac.gonzalez@clin.au.dk